The Federal Department of Health’s Office of Drug Control (ODC) yesterday approved manufacturing licences for Cann Group’s existing Northern and Southern medicinal cannabis facilities in Melbourne.
Cann Group said the licences relate to the manufacturing, packaging, storage, transport and disposal of medicinal cannabis in final dose and intermediate forms, with appropriate permits to be required ‘in relation to the undertaking of specific activities under the licences’.
Cann Group CEO, Peter Crock noted that the company now holds all cultivation, production and manufacture licences under the Narcotics Drugs Act, along with import and export licences under the Customs Act.
He said the licences will complement the manufacturing arrangements in place with IDT Australia Ltd, which was granted its ODC manufacturing licence in May.
“Securing our ODC manufacturing licences is an important milestone that supports our fully integrated business model strategy. The ability to undertake these activities at both our Northern and Southern facilities gives us considerable flexibility as we continue to progress the development of our new state-of-the-art cultivation facility near Mildura.” Mr Crock said.
“IDT, which has GMP approved facilities, offers us immediate access to proven expertise in pharmaceutical manufacturing while we continue to develop our own capabilities.”